Shareholders Equity (Quarterly) Chart

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 192.00M
June 30, 2026 219.26M
March 31, 2026 246.49M
December 31, 2025 284.34M
September 30, 2025 193.93M
June 30, 2025 206.36M
March 31, 2025 192.01M
December 31, 2024 204.08M
September 30, 2024 215.28M
June 30, 2024 192.92M
March 31, 2024 198.17M
December 31, 2023 50.68M
Date Value
September 30, 2023 204.02M
June 30, 2023 224.15M
March 31, 2023 276.22M
December 31, 2022 296.29M
September 30, 2022 316.45M
June 30, 2022 338.46M
March 31, 2022 361.30M
December 31, 2021 389.84M
September 30, 2021 400.13M
June 30, 2021 379.18M
March 31, 2021 176.46M
December 31, 2020 -9.80M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
EyePoint, Inc. 108.51M
Ligand Pharmaceuticals, Inc. 961.76M
Bristol Myers Squibb Co. 23.40B
Context Therapeutics, Inc. 31.01M
Neumora Therapeutics, Inc. 18.55M

Shareholders Equity (Quarterly) Related Metrics